State Street Corp Acquires 16,248 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

State Street Corp grew its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 384,732 shares of the company’s stock after acquiring an additional 16,248 shares during the period. State Street Corp owned 0.76% of Tyra Biosciences worth $9,045,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TYRA. American Century Companies Inc. increased its holdings in shares of Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after buying an additional 145,346 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Tyra Biosciences in the 3rd quarter worth approximately $24,994,000. Ensign Peak Advisors Inc purchased a new stake in Tyra Biosciences in the second quarter worth approximately $3,047,000. Finally, Polar Asset Management Partners Inc. bought a new position in Tyra Biosciences during the third quarter valued at approximately $2,071,000. 84.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TYRA has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright cut their target price on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, Oppenheimer raised their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.00.

Insiders Place Their Bets

In other news, CFO Alan Fuhrman acquired 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the purchase, the chief financial officer now directly owns 12,849 shares in the company, valued at $205,584. This trade represents a 283.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd Harris sold 10,035 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $24.31, for a total value of $243,950.85. Following the transaction, the chief executive officer now owns 1,467,338 shares in the company, valued at approximately $35,670,986.78. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 84,660 shares of company stock valued at $1,839,047 over the last 90 days. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $14.70 on Friday. Tyra Biosciences, Inc. has a 1 year low of $11.24 and a 1 year high of $29.60. The firm’s 50 day moving average price is $17.34 and its 200-day moving average price is $19.47. The stock has a market cap of $743.86 million, a P/E ratio of -9.13 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.